 methylnaltrexone bromide |
| Relistor |
Pharmaceutical
company:
Wyeth
www.wyeth.com |
Pharmacologic classification: opioid receptor antagonist
Therapeutic classification: laxative
Pregnancy risk category: B
AVAILABLE FORMS
Injection: 12 mg/0.6 ml single-use vials
INDICATIONS AND DOSAGES
Opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy hasn't been sufficient--
Adults weighing from 38 kg (84 lb) to less than 62 kg (137 lb): 8 mg subcutaneously every other day, as needed.
Adults weighing from 62 kg to 114 kg (251 lb): 12 mg subcutaneously every other day, as needed.
Adults weighing less than 38 kg or more than 114 kg: 0.15 mg/kg per dose subcutaneously every other day, as needed, not to exceed one dose in 24 hours.
ADJUST-A-DOSE:
For patients with severe renal impairment, reduce dose by one-half.
CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients hypersensitive to methylnaltrexone or any component of the drug, and in those with known or suspected mechanical GI obstruction.
Use cautiously in patients with moderate renal impairment and in pregnant or breast-feeding patients.
INTERACTIONS
None reported.
ADVERSE REACTIONS
CV: dizziness.
GI: abdominal pain, flatulence, nausea, diarrhea.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
